Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPSANCHES-GIRAUD, CristinaGOMEZ, David S.CAMPOS, Edvaldo V.AZEVEDO, Rodrigo P. deDESPINOY, AlessandraPEREZ, Grazziela S.FERREIRA, Marcus C.SANTOS, Silvia R. C. J.2017-11-272017-11-272011LATIN AMERICAN JOURNAL OF PHARMACY, v.30, n.8, p.1468-1474, 20110326-2383https://observatorio.fm.usp.br/handle/OPI/22455A bioanalytical micromethod was described for the quantification of amphotericin B in plasma by HPLC. The method showed high absolute recovery, good linearity (0.1-10.0 mu g/mL, r(2) = 0.999), sensitivity (limits of quantification: 0.1 mu g/mL), and acceptable stability. Inter/intraday precisions were 6.8 %/23 % and mean accuracy was 94.3 %. The method was applied to plasma monitoring of one burn child, 3 years old, 25 kg, thermal injury (18 % total burn surface area - TBSA). Amphotericin B (1 mg/kg) was prescribed from 24(tg) to 35(tg) day of the accident and plasma monitoring and pharmacokinetics was performed by serial blood collections on 274 and 354 days post burn. Plasma concentrations obtained were respectively 0.7 mu g/mL and 1.2 mu g/mL. Pharmacokinetics at both periods (27(tg) vs 35(tg) day) also was compared: 13.8 vs 14.3 h (t(1/2 beta)); 0.5 vs 03 mL/min.kg (CL(T)) and 0.65 vs 038 L/kg (Vd(ss)). In conclusion, drug plasma monitoring by HPLC was quite useful to guarantee low risk and drug efficacy in a paediatric burn patient.engrestrictedAccessAmphotericin BBurn childDrug plasma monitoringHPLC-UVPharmacokineticsinternal standardmalignant diseaseshuman-serumpharmacokineticsassaypharmacodynamicsextractionarticleCopyright COLEGIO FARMACEUTICOS PROVINCIA DE BUENOS AIRESPharmacology & Pharmacy